Evaluation of an IV Insulin Electronic Glucose Management System Using FDA Cleared Feature of EREI (Estimated Residual Extracellular Insulin) to Prevent Severe Hypoglycemia
Objective
This retrospective review examines effects of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature on glycemic control of patients receiving intravenous insulin.
Setting
Cohort of 30 community hospitals.
Results
- With the EREI adjustment feature enabled, median time to goal was 3.3 hours for a range of 140-180 mg/dL and 135-155 mg/dL.
- With the EREI adjustment feature enabled, incidence of severe hypoglycemia <40 mg/dL was 0.009% of blood glucose readings for a range of 140-180 mg/dL and .0007% of blood glucose readings for a range of 135-155 mg/dL.
Conclusions
Use of the specialized EndoTool EREI adjustment feature creates the potential to eliminate severe hypoglycemia while achieving target glucose levels and provides additional safety to the dosing of intravenous insulin without the human error and confusion associated with paper protocols.
Authors
W. Patrick Burgess, PhD, MD; Laurel Fuqua, RN, MSN.
Source
Presented at International Conference on Advanced Technologies & Treatments for Diabetes. Published in Diabetes Technology & Therapeutics, Volume 22, Issue S1, p584.
Year
2020
Tags
- Cost Savings
- Healthcare-Associated Infections
- Hospital-Acquired Conditions
- Hyperglycemia Reduction
- Hypoglycemia Reduction
- Length of Stay
- Surgical Site Infections
- Glucose Variability
- Mean Glucose Improvement
- Target Goal Attainment
- Time in Range
- Time on IV Insulin
- Time to Target
- Burn Injury
- Cardiac Surgery
- DKA/HHS Management
- Emergency Department
- Induced Hypothermia
- Intra-op Glucose Management
- Obstetrics/Labor & Delivery
- Pediatrics
- Residual Insulin Adjustment
- BG Check Compliance
- BG Test Reduction
- Nursing Satisfaction
- Protocol Adherence
- Provider Satisfaction
- Workflow Improvements